Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog – Page 29

Get the latest international news and world events from around the world.

Log in for authorized contributors

Photonic processor could streamline 6G wireless signal processing

One of the biggest challenges the researchers faced when designing MAFT-ONN was determining how to map the machine-learning computations to the optical hardware.

“We couldn’t just take a normal machine-learning framework off the shelf and use it. We had to customize it to fit the hardware and figure out how to exploit the physics so it would perform the computations we wanted it to,” Davis says.

When they tested their architecture on signal classification in simulations, the optical neural network achieved 85 percent accuracy in a single shot, which can quickly converge to more than 99 percent accuracy using multiple measurements. MAFT-ONN only required about 120 nanoseconds to perform entire process.

Lung cancer drug offers a surprising new treatment against ovarian cancer

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this class of drugs work better. The research is published in the journal Science Translational Medicine.

PARP inhibitors are a common treatment for ovarian cancer and can be especially effective in cancers with impaired DNA repair. However, many tumors eventually stop responding, even when the drugs initially show results. The new research identifies a way cancer cells may survive PARP inhibitor treatment early on, and it points to a potential strategy to block that response.

In the study, researchers found that ovarian cancer cells rapidly activate a pro-survival program after exposure to PARP inhibitors. A key driver of this response is FRA1, a transcription factor that helps turn on genes that allow cancer cells to adapt and avoid cell death.

Gemini 3 Deep Think: Advancing science, research and engineering

Today, we’re releasing a major upgrade to Gemini 3 Deep Think, our specialized reasoning mode, built to push the frontier of intelligence and solve modern challenges across science, research, and engineering.

We updated Gemini 3 Deep Think in close partnership with scientists and researchers to tackle tough research challenges — where problems often lack clear guardrails or a single correct solution and data is often messy or incomplete. By blending deep scientific knowledge with everyday engineering utility, Deep Think moves beyond abstract theory to drive practical applications.

The new Deep Think is now available in the Gemini app for Google AI Ultra subscribers and, for the first time, we’re also making Deep Think available via the Gemini API to select researchers, engineers and enterprises. Express interest in early access here.

Impact of Etiology on Mortality and Recovery in Patients With Status Epilepticus

Background and ObjectivesAlthough etiology is considered central to outcomes in status epilepticus (SE), previous studies often lacked standardized classification and adjustment for confounders, particularly withdrawal of life-sustaining treatment (WLST)…

Spinal Cord Organoids Help Test Paralysis Treatment

What if we could test spinal cord injury therapies in human tissue without a clinical trial?

It could be possible, as spinal cord organoids derived from human stem cells now replicate real injury responses.

Read more.

Organoids developed from human stem cells modeled spinal cord injuries, providing a powerful in vitro tool to evaluate regenerative therapies for CNS injuries.

Effective connectivity between homologous cortices mediated by the corpus callosum: An axono-cortical evoked potentials study

[Functional brain mapping] Mitsuhashi et al.: “Callosal stimulation showed effective connectivity to homologous cortical regions. Sum of callosal-to-cortex propagation latencies matched interhemispheric latency.” Open access.

All content on this site: Copyright © 2026 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.

/* */